vs
PREFORMED LINE PRODUCTS CO（PLPC）与再鼎医药（ZLAB）财务数据对比。点击上方公司名可切换其他公司
PREFORMED LINE PRODUCTS CO的季度营收约是再鼎医药的1.4倍（$173.1M vs $127.1M），再鼎医药同比增速更快（17.1% vs 3.6%），PREFORMED LINE PRODUCTS CO自由现金流更多（$11.8M vs $-26.7M），过去两年再鼎医药的营收复合增速更高（20.8% vs 10.8%）
预成型线路产品公司（PLPC）研发、生产和销售适用于输配电、通信及可再生能源基建领域的工程硬件组件，服务全球多地的公用事业、网络运营商及工业客户，提供可提升网络可靠性与运营效率的解决方案。
再鼎医药是一家创新生物制药企业，专注于肿瘤、自身免疫性疾病、感染性疾病等领域创新疗法的研发、生产与商业化，核心市场覆盖大中华区，与全球多家头部生物科技企业合作，为存在未被满足医疗需求的患者提供治疗方案。
PLPC vs ZLAB — 直观对比
营收规模更大
PLPC
是对方的1.4倍
$127.1M
营收增速更快
ZLAB
高出13.5%
3.6%
自由现金流更多
PLPC
多$38.5M
$-26.7M
两年增速更快
ZLAB
近两年复合增速
10.8%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $173.1M | $127.1M |
| 净利润 | $8.4M | — |
| 毛利率 | 29.8% | 51.0% |
| 营业利润率 | 6.8% | -54.6% |
| 净利率 | 4.9% | — |
| 营收同比 | 3.6% | 17.1% |
| 净利润同比 | -19.3% | — |
| 每股收益（稀释后） | $1.72 | $-0.05 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收PLPCZLAB
| Q4 25 | $173.1M | $127.1M | ||
| Q3 25 | $178.1M | $115.4M | ||
| Q2 25 | $169.6M | $109.1M | ||
| Q1 25 | $148.5M | $105.7M | ||
| Q4 24 | $167.1M | $108.5M | ||
| Q3 24 | $147.0M | $101.8M | ||
| Q2 24 | $138.7M | $100.1M | ||
| Q1 24 | $140.9M | $87.1M |
净利润PLPCZLAB
| Q4 25 | $8.4M | — | ||
| Q3 25 | $2.6M | $-36.0M | ||
| Q2 25 | $12.7M | $-40.7M | ||
| Q1 25 | $11.5M | $-48.4M | ||
| Q4 24 | $10.5M | — | ||
| Q3 24 | $7.7M | $-41.7M | ||
| Q2 24 | $9.4M | $-80.3M | ||
| Q1 24 | $9.6M | $-53.5M |
毛利率PLPCZLAB
| Q4 25 | 29.8% | 51.0% | ||
| Q3 25 | 29.7% | 59.5% | ||
| Q2 25 | 32.7% | 60.6% | ||
| Q1 25 | 32.8% | 63.6% | ||
| Q4 24 | 33.3% | 61.5% | ||
| Q3 24 | 31.1% | 64.1% | ||
| Q2 24 | 31.9% | 64.9% | ||
| Q1 24 | 31.3% | 61.4% |
营业利润率PLPCZLAB
| Q4 25 | 6.8% | -54.6% | ||
| Q3 25 | 7.4% | -42.3% | ||
| Q2 25 | 10.1% | -50.3% | ||
| Q1 25 | 8.8% | -53.3% | ||
| Q4 24 | 10.5% | -62.6% | ||
| Q3 24 | 7.1% | -66.6% | ||
| Q2 24 | 8.1% | -76.0% | ||
| Q1 24 | 8.2% | -80.7% |
净利率PLPCZLAB
| Q4 25 | 4.9% | — | ||
| Q3 25 | 1.5% | -31.2% | ||
| Q2 25 | 7.5% | -37.3% | ||
| Q1 25 | 7.8% | -45.8% | ||
| Q4 24 | 6.3% | — | ||
| Q3 24 | 5.2% | -40.9% | ||
| Q2 24 | 6.8% | -80.2% | ||
| Q1 24 | 6.8% | -61.4% |
每股收益（稀释后）PLPCZLAB
| Q4 25 | $1.72 | $-0.05 | ||
| Q3 25 | $0.53 | $-0.03 | ||
| Q2 25 | $2.56 | $-0.04 | ||
| Q1 25 | $2.33 | $-0.04 | ||
| Q4 24 | $2.13 | $-0.09 | ||
| Q3 24 | $1.54 | $-0.04 | ||
| Q2 24 | $1.89 | $-0.08 | ||
| Q1 24 | $1.94 | $-0.05 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | — | $689.6M |
| 总债务越低越好 | $38.3M | — |
| 股东权益账面价值 | $475.5M | $715.5M |
| 总资产 | $653.6M | $1.2B |
| 负债/权益比越低杠杆越低 | 0.08× | — |
8季度趋势，按日历期对齐
现金及短期投资PLPCZLAB
| Q4 25 | — | $689.6M | ||
| Q3 25 | — | $717.2M | ||
| Q2 25 | — | $732.2M | ||
| Q1 25 | — | $757.3M | ||
| Q4 24 | — | $779.7M | ||
| Q3 24 | — | $616.1M | ||
| Q2 24 | — | $630.0M | ||
| Q1 24 | — | $650.8M |
总债务PLPCZLAB
| Q4 25 | $38.3M | — | ||
| Q3 25 | $36.0M | — | ||
| Q2 25 | $31.8M | — | ||
| Q1 25 | $29.1M | — | ||
| Q4 24 | $20.8M | — | ||
| Q3 24 | $27.2M | — | ||
| Q2 24 | $31.6M | — | ||
| Q1 24 | $55.0M | — |
股东权益PLPCZLAB
| Q4 25 | $475.5M | $715.5M | ||
| Q3 25 | $466.3M | $759.9M | ||
| Q2 25 | $460.7M | $791.7M | ||
| Q1 25 | $435.8M | $810.8M | ||
| Q4 24 | $422.3M | $840.9M | ||
| Q3 24 | $429.0M | $667.7M | ||
| Q2 24 | $416.2M | $704.2M | ||
| Q1 24 | $413.4M | $762.2M |
总资产PLPCZLAB
| Q4 25 | $653.6M | $1.2B | ||
| Q3 25 | $644.6M | $1.2B | ||
| Q2 25 | $631.5M | $1.2B | ||
| Q1 25 | $592.5M | $1.2B | ||
| Q4 24 | $573.9M | $1.2B | ||
| Q3 24 | $592.0M | $985.3M | ||
| Q2 24 | $572.6M | $987.4M | ||
| Q1 24 | $586.1M | $988.4M |
负债/权益比PLPCZLAB
| Q4 25 | 0.08× | — | ||
| Q3 25 | 0.08× | — | ||
| Q2 25 | 0.07× | — | ||
| Q1 25 | 0.07× | — | ||
| Q4 24 | 0.05× | — | ||
| Q3 24 | 0.06× | — | ||
| Q2 24 | 0.08× | — | ||
| Q1 24 | 0.13× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $21.9M | $-26.0M |
| 自由现金流经营现金流 - 资本支出 | $11.8M | $-26.7M |
| 自由现金流率自由现金流/营收 | 6.8% | -21.0% |
| 资本支出强度资本支出/营收 | 5.9% | 0.5% |
| 现金转化率经营现金流/净利润 | 2.60× | — |
| 过去12个月自由现金流最近4个季度 | $33.3M | $-158.9M |
8季度趋势，按日历期对齐
经营现金流PLPCZLAB
| Q4 25 | $21.9M | $-26.0M | ||
| Q3 25 | $18.9M | $-32.0M | ||
| Q2 25 | $26.9M | $-31.0M | ||
| Q1 25 | $5.7M | $-61.7M | ||
| Q4 24 | $24.1M | $-55.8M | ||
| Q3 24 | $9.4M | $-26.8M | ||
| Q2 24 | $28.3M | $-42.2M | ||
| Q1 24 | $5.8M | $-90.1M |
自由现金流PLPCZLAB
| Q4 25 | $11.8M | $-26.7M | ||
| Q3 25 | $8.3M | $-35.0M | ||
| Q2 25 | $18.6M | $-33.9M | ||
| Q1 25 | $-5.3M | $-63.2M | ||
| Q4 24 | $20.6M | $-58.4M | ||
| Q3 24 | $5.8M | $-28.2M | ||
| Q2 24 | $24.6M | $-42.9M | ||
| Q1 24 | $1.8M | $-91.1M |
自由现金流率PLPCZLAB
| Q4 25 | 6.8% | -21.0% | ||
| Q3 25 | 4.7% | -30.4% | ||
| Q2 25 | 10.9% | -31.1% | ||
| Q1 25 | -3.6% | -59.9% | ||
| Q4 24 | 12.3% | -53.8% | ||
| Q3 24 | 3.9% | -27.7% | ||
| Q2 24 | 17.7% | -42.9% | ||
| Q1 24 | 1.3% | -104.5% |
资本支出强度PLPCZLAB
| Q4 25 | 5.9% | 0.5% | ||
| Q3 25 | 6.0% | 2.6% | ||
| Q2 25 | 4.9% | 2.6% | ||
| Q1 25 | 7.4% | 1.5% | ||
| Q4 24 | 2.1% | 2.4% | ||
| Q3 24 | 2.4% | 1.3% | ||
| Q2 24 | 2.7% | 0.7% | ||
| Q1 24 | 2.8% | 1.1% |
现金转化率PLPCZLAB
| Q4 25 | 2.60× | — | ||
| Q3 25 | 7.21× | — | ||
| Q2 25 | 2.12× | — | ||
| Q1 25 | 0.49× | — | ||
| Q4 24 | 2.30× | — | ||
| Q3 24 | 1.22× | — | ||
| Q2 24 | 3.02× | — | ||
| Q1 24 | 0.60× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
PLPC
暂无分部数据
ZLAB
| Zejula | $56.0M | 44% |
| Other | $21.9M | 17% |
| Nuzyra | $16.0M | 13% |
| Optune | $11.9M | 9% |
| XACDURO | $10.7M | 8% |
| Qinlock | $9.7M | 8% |
| AUGTYRO | $836.0K | 1% |
